Lyell Immunopharma Insider ARCH Venture Partners IX LLC Buys $25M of Stock
ARCH Venture Partners IX LLC bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 a share, worth $25M in total on Nov 4, 2026. Shares held after the trade: 3,747,790 (+162.7%).
Lyell Immunopharma Insider ARCH Venture Fund XIII L.P. Buys $25M of Stock
ARCH Venture Fund XIII L.P. bought 2,321,262 shares of Lyell Immunopharma, Inc. at $10.77 a share, worth $25M in total on Nov 4, 2026. Shares held after the trade: 3,747,790 (+162.7%).
Lyell Immunopharma reported total assets of $273.9 million as of September 30, 2026, a decrease from $340.1 million at the end of 2025. The company's liquidity is primarily held in cash, cash equivalents, and marketable securities totaling approximately $194 million, which it intends to use to fund the development of its lead product candidates, ronde-cel and LYL273.
Lyell Immunopharma reported Q3 2026 financial results and provided clinical updates for its CAR T-cell therapy ronde-cel, which showed a 91% overall response rate in the PiNACLE trial. The company also announced an $80 million private placement financing, extending its cash runway into 2028.
“The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma. The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel.”
Lynn Seely, M.D., President and Chief Executive Officer of Lyell
Lyell Immunopharma entered into a securities purchase agreement to raise $80.0 million through a private placement of 7,428,040 shares of common stock. The shares were sold to institutional accredited investors at a price of $10.77 per share, with the company agreeing to file a resale registration statement within 30 days of closing.